Jasper Therapeutics Management

Management criteria checks 0/4

Jasper Therapeutics' CEO is Ron Martell, appointed in Mar 2022, has a tenure of 2.17 years. total yearly compensation is $5.77M, comprised of 8.8% salary and 91.2% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth $790.55K. The average tenure of the management team and the board of directors is 1.8 years and 2.4 years respectively.

Key information

Ron Martell

Chief executive officer

US$5.8m

Total compensation

CEO salary percentage	8.8%
CEO tenure	2.2yrs
CEO ownership	0.2%
Management average tenure	1.8yrs
Board average tenure	2.4yrs

Recent management updates

Recent updates

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Jan 23

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Jul 31

Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning

Nov 28

We Think Jasper Therapeutics (NASDAQ:JSPR) Can Afford To Drive Business Growth

Nov 23

CEO Compensation Analysis

How has Ron Martell's remuneration changed compared to Jasper Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$64m
Sep 30 2023	n/a	n/a	-US$61m
Jun 30 2023	n/a	n/a	-US$55m
Mar 31 2023	n/a	n/a	-US$50m
Dec 31 2022	US$6m	US$510k	-US$38m

Compensation vs Market: Ron's total compensation ($USD5.77M) is above average for companies of similar size in the US market ($USD2.41M).

Compensation vs Earnings: Insufficient data to compare Ron's compensation with company performance.

CEO

Ron Martell (61 yo)

2.2yrs

Tenure

US$5,771,174

Compensation

Mr. Ronald A. Martell, also known as Ron, serves as President, Chief Executive Officer & Director at Jasper Therapeutics, Inc. since March 15, 2022. He has been Chief Financial Officer and Director at Morp...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ronald Martell	President	2.2yrs	US$5.77m	0.22% $ 790.5k
Judith Shizuru	Co-Founder & Director	no data	US$513.13k	0.77% $ 2.8m
Jeetinder Mahal	Chief Operating Officer	2.2yrs	US$1.11m	0.17% $ 597.0k
Herbert Cross	CFO & Corporate Secretary	less than a year	no data	no data
Luca Di Noto	Senior Vice President of Technical Operations	4.3yrs	no data	no data
David Ku	Vice President of Corporate Development	no data	no data	no data
Matthew Ford	Vice President of Human Resources	1.3yrs	no data	no data
Wendy Pang	Senior Vice President of Research & Translational Medicine	2.2yrs	no data	no data
Edwin Tucker	Chief Medical Officer	less than a year	no data	no data
Patricia Carlos	Senior Vice President of Regulatory Affairs & Quality	less than a year	no data	no data

1.8yrs

Average Tenure

51yo

Average Age

Experienced Management: JSPR's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Ronald Martell	President	2.2yrs	US$5.77m	0.22% $ 790.5k
Judith Shizuru	Co-Founder & Director	6.2yrs	US$513.13k	0.77% $ 2.8m
Thomas Wiggans	Independent Chairman	less than a year	no data	0.033% $ 119.3k
Kurt von Emster	Independent Director	4.5yrs	US$284.23k	0.0040% $ 14.4k
Daniel Adelman	Member of Scientific Advisory Board & Senior Clinical Advisor	less than a year	no data	no data
Arthur Weiss	Member of Scientific Advisory Board	no data	no data	no data
Frederick Appelbaum	Member of Scientific Advisory Board	no data	no data	no data
Jeffrey Ravetch	Member of Scientific Advisory Board	no data	no data	no data
Anna French	Independent Director	4.5yrs	US$284.07k	0.0056% $ 20.0k
Vishal Kapoor	Independent Director	1.3yrs	no data	0.029% $ 104.4k
Harry Malech	Member of Scientific Advisory Board	no data	no data	no data
Christian Nolet	Independent Director	2.7yrs	US$285.81k	0.022% $ 77.6k

2.4yrs

Average Tenure

66yo

Average Age

Experienced Board: JSPR's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Jasper Therapeutics Management

Management criteria checks 0/4

Key information

Recent management updates

Jasper Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Less than half of directors are independent

Jasper Therapeutics, Inc. Announces Board Changes

Jasper Therapeutics, Inc. Announces Chief Financial Officer Changes

Jasper Therapeutics Strengthens Management Team with Key Appointments

Jasper Therapeutics, Inc. Appoints Scott Brun to Its Board of Directors

Recent updates

Jasper Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

Jasper Therapeutics, Inc. Announces Additional Positive Phase 1b/2a Data on Briquilimab as A Conditioning Agent in the Treatment of Fanconi Anemia

Jasper Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50.505 million.

New major risk - Share price stability

Jasper Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $50.505 million.

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Price target decreased by 11% to US$61.25

Jasper Therapeutics Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of Common Stock for Continued Listing on the Nasdaq Capital Market

Jasper Therapeutics, Inc. Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation At ASH 2023

Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1B/2A Clinical Study of Briquilimab in Chronic Spontaneous Urticaria

Less than half of directors are independent

Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023

Jasper Therapeutics, Inc. Announces Board Changes

Jasper Therapeutics Receives Written Notice from Nasdaq Regarding Minimum $1.00 Per Share Requirement

Jasper Therapeutics, Inc. Announces Chief Financial Officer Changes

Price target increased by 9.8% to US$6.88

New major risk - Revenue and earnings growth

Jasper Therapeutics Strengthens Management Team with Key Appointments

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Jasper Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome

Jasper Therapeutics, Inc. Appoints Scott Brun to Its Board of Directors

CFO, COO & Corporate Secretary notifies of intention to sell stock

Jasper Therapeutics, Inc. Announces Appointment of Edwin J. Tucker as Chief Medical Officer

Jasper Therapeutics, Inc. Announces Appointment of Stephen J. Galli to Scientific Advisory Board

Jasper Therapeutics, Inc. Appoints Vishal Kapoor as Class I Director

Price target increased by 11% to US$5.97

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Price target decreased by 9.0% to US$7.10

Jasper Therapeutics, Inc. Announces New Positive Briquilimab Data to Be Presented at the 2023 Tandem Meetings

Jasper Therapeutics, Inc. Announces Development Prioritization of Briquilimab in Chronic Diseases

Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as A Conditioning Treatment for Patients Prior to Receiving A Stem Cell Transplant

Jasper Therapeutics, Inc. Announces Positive Clinical Data from A Phase I/Ii Trial of Briquilimab as A Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia

Price target decreased to US$7.80

High number of new directors

Price target decreased to US$12.00

Jasper Therapeutics Receives Written Notice from Nasdaq

Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely

Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting

Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, A Novel Monoclonal Antibody Targeting CD117, in the Treatment of Patients with Severe Combined Immunodeficiency (SCID) Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Price target decreased to US$12.25

Jasper Therapeutics GAAP EPS of -$0.29 beats by $0.02

Non-Executive Chairperson of the Board notifies of intention to sell stock

Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Invest In Growth?

Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia

Jasper Therapeutics, Inc. Announces Development of Novel Curative Therapies Based on the Biology of the Hematopoietic Stem Cell

Jasper Therapeutics, Inc., Annual General Meeting, Jun 23, 2022

High number of new directors

Jasper Therapeutics, Inc. Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

High number of new directors

Jasper Therapeutics, Inc. Announces Executive Changes

Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning

We Think Jasper Therapeutics (NASDAQ:JSPR) Can Afford To Drive Business Growth

No independent directors

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age